Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX-af01 + Toripalimab in Refractory Advanced Solid Tumors
NCT05576961Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label trial of RX-AF01 in solid tumor (3 arms), sponsored by Sun Yat-sen University. Primary endpoints: Safety and Efficacy of bacterial strain RX-af01 in combination with toripalimab and Objective Response Rate at 1 year. Started Sep 2022; status: recruiting.
02
Drugs
RX-AF01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05576961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576961.